Cancer Cause and Prevention Research in New York
Cancer Cause and Prevention Research (93.393) awarded $445 million to recipients in New York in 295 grants from fiscal 2021 to 2025, 12% of the program's national total. Sloan-Kettering Institute for Cancer Research received the most, $99.1 million.
- Awarded in New York$445 million
- Awards295
- Share of the program12%
- Rank among states2nd of 48
- National total$3.6 billion
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 149 | $84.4 million |
| FY 2022 | 161 | $90.9 million |
| FY 2023 | 165 | $93.9 million |
| FY 2024 | 159 | $86.6 million |
| FY 2025 | 146 | $89.6 million |
Recipients in New York
| Recipient | Type | Awards | Amount |
|---|---|---|---|
| Sloan-Kettering Institute for Cancer Research | Nonprofits | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | Colleges and universities | 48 | $85.3 million |
| New York University | Colleges and universities | 25 | $52.2 million |
| Health Research, Inc. | Nonprofits | 25 | $47.8 million |
| Icahn School of Medicine at Mount Sinai | Colleges and universities | 25 | $42.1 million |
| Weill Medical College of Cornell University | Colleges and universities | 25 | $27.7 million |
| Albert Einstein College of Medicine | Colleges and universities | 13 | $18.2 million |
| The Rockefeller University | Colleges and universities | 10 | $14.3 million |
| The Research Foundation for the State University of New York | Other | 7 | $10.7 million |
| University of Rochester | Colleges and universities | 13 | $10.1 million |
Open opportunities under this program
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
- Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
See all 60 on the program page
Questions people ask
How much Cancer Cause and Prevention Research money goes to New York?
$445 million from fiscal 2021 to 2025, across 295 awards. New York ranks 2nd of 48 states and territories for this program.
Who receives Cancer Cause and Prevention Research money in New York?
The largest recipient is Sloan-Kettering Institute for Cancer Research, with $99.1 million in 65 awards. Next are The Trustees of Columbia University in the City of New York and New York University.
Can organizations in New York apply now?
Yes, 60 opportunities under this program are open or forecast on Grants.gov. Federal grants are national, so eligibility depends on the notice, not the state.
Cancer Cause and Prevention Research in other states
Other large programs in New York
- Grants to States for Medicaid
- 1332 State Innovation Waivers
- Federal Transit Formula Grants
- Education Stabilization Fund
- Disaster Grants - Public Assistance (Presidentially Declared Disasters)
- Temporary Assistance for Needy Families
- Highway Planning and Construction
- National School Lunch Program
- Children's Health Insurance Program
- Public Housing Operating Fund